Conformational variants of the unique family of protease inhibitors annotated as SERPINs, are most often underrepresented in proteomic analyses. This limits understanding the complex regulation that this family of proteins presents to the networks within the protease web of interactions. Using bead-based separation provided by the NuGel™ family of proteomic enrichment products -notably AlbuVoid™ & AlbuSorb™, we demonstrate their utility to satisfy investigations of serum SERPINs. We also suggest their use to develop functional profiles of the SERPIN proteoforms, and how those can establish relationships to disease phenotypes, gene mutations, and dysregulated mechanisms.
Introduction and Objectives
The balance and regulation of proteolytic activity within serum is essential to blood based biomarker discovery and possibly to therapeutic intervention. Changes in blood components often reflect acute responses to thwart external stresses, such as coagulation when skin is severed, or inflammatory response during microbial infections.
These fast-acting responses are controlled by proteolytic cascades, essentially modifying functionality by the controlled degradation of protein structures. While necessary for acute response, persistent activation of these proteolytic cascades can lead to chronic conditions. So, there is a balance and regulation of these proteolytic cascades which is necessary to keep aberrant proteolysis controlled. It is therefore necessary to consider that inhibitors are themselves being regulated under different and often complex means of regulation. Within this context, therein lies the special case of the SERPIN superfamily of protease inhibitors.
The Functional Subproteomes of SERPIN Protease Inhibitors Are Now Open For LC-MS Biomarker Discovery

The SERPIN Super-family of Suicidal Inhibitors
There are many different families of protease inhibitors, This is because SERPINs differ from all other families of protease inhibitors in having a complex mechanism of action that involves a drastic change in their shape, forming the basis of a suicidal substrate inhibition mechanism 2, 3 . The reactive centre loop (RCL) extends out from the body of the protein and directs binding to the target protease. The protease cleaves the . The resulting inactive serpin-protease complex is highly stable, and the structural disorder induces its proteolytic inactivation. As a consequence, the protease is permanently inhibited and functionally inactivated. Nevertheless, the story does not end there for the inhibitor, as after the initial interaction with the substrate protease, one of two possible outcomes can occur.
One possible outcome is driven by covalent modification permanently inactivating the inhibitory capacity as the SERPIN peptide reactive bond region is irreversibly bound to the protease, and thus cannot be reconstituted back to an active form.
The second possible outcome is a permanently inactive or "killed" proteoform of the SERPIN as the peptide RCL region is cleaved and can no longer bind target substrates 4 .
As a result, even minor changes in the structure due to genetic variation and post-translational modifications, can modify the function of SERPINs and give rise to a variety of clinical presentations. Some 200 different mutations in serpins are known to result in disease 5 . In particular, mutations affecting antithrombin confer a predisposition to thrombosis, those affecting C1
inhibitor confer a predisposition to angioedema, and those affecting antiplasmin confer a predisposition to hemorrhage.
Interestingly, an alternative function is made possible by a mutation in which the methionine in the RCL region of Alpha-1-Antitrypsin is replaced by an arginine converting its function as an inhibitor of neutrophil elastase to a highly effective inhibitor of the coagulation proteases; the consequence of which is life-threatening hemorrhagic disease 6 .
The So understanding the underlying mechanisms, contributions from genetic wiring or environmental stresses, and their relationships with aberrant proteolysis are necessary to characterize disease. Proteomic analyses offer a new lens of observation to examine the resulting conformational variants that can be reported as potential biomarkers of disease phenotypes. As an example, one such inhibitor SERPINA1, known more commonly as Alpha-1-Antitrypsin (AAT), has several isoforms observed in plasma using 2-DE, and often serves as a model for conformational diseases 5, 9 . Circulating levels of AAT are between 1.2 and 2 mg/ml in healthy persons, but are known to increase during acute phases of inflammation and infection. Its function and activity is controlled by the many variants attributable to its conformational nexus of features; the term 'proteoform' is often used to describe such conformation features and we adopt that term here.
Several reports observe that the conformational properties of AAT have multiple effects on tumor cell viability and diverse roles in tumorigenesis, suggesting such isoforms may display a specific basis for diagnosis of cancer and neurodegenerative disorders 8, 10, 11 . Yet, most often in proteomics, all sub-populations of AAT are rolled into and counted as one homogeneous population, or as in the case of immuno-depletion, simply ignored as background noise. As a result, the regulation, balance and dynamism within these systems and its impact on the protease web of disease progression cannot be properly investigated.
BSG Products Can Help Count Proteins Differently
By combining our unique strategies of binding and voiding high abundance proteins, we can observe different subpopulations with characteristic binding biases. We have previously reported for Alpha-1-Antitrypsin, that the resultant cleaved-RCL proteoform, and the uncleaved-RCL proteoform are very distinctive sub-populations, separated by AlbuVoid™, and reported at the peptide feature level by LC-MS 12 . In this report, we consider how our Albumin Removal productsAlbuVoid™ and AlbuSorb™, can help to functionally profile and unravel this complex world of the SERPIN superfamily of proteins.
Albumin Removal Technology based on NuGel™ Silica Surface Chemistry
Through a proprietary polymer coating, 50 µm porous silica beads are crosslinked and passivated. This is the foundation of 
INACTIVE subpopulations
In this model case, the ratio of the ACTIVE sub-population vs. the INACTIVE sub-population is greatly altered in disease, whereas simple abundance measurements of the total population would not be very informative. In the following 
